SCHEMBL10243088

SCHEMBL10243088

COC(=O)Cc1cccc(CNCCOc2cccc3cccnc23)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 1/20 0.48
GAA P10253 2/20 0.48
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GLRA3 O75311 2/20 0.46
GLRB P48167 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 2/20 0.45
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
TLR7 Q9NYK1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243064 0.84 POLB (0.52) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL10243087 0.83 POLB (0.67) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL10243092 0.81 ALDH1A1 (0.47) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL10243353 0.80 MEN1 (0.47) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL12028680 0.78 SLC7A5 (0.55) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL10243056 0.77 DRD4 (0.60) ALDH1A1MEN1KMT2AKDM4EMAPK1
SCHEMBL7765107 0.74 GLRA3 (0.53) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL12028729 0.74 SLC7A5 (0.56) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL1101354 0.73 RAB9A (0.60) POLBALDH1A1MEN1KMT2AKDM4E
SCHEMBL3453971 0.73 KDM4E (0.64) POLBALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 POLB 3348/4885ALDH1A1 1939/4885MEN1 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.